Mosquito saliva peptide vaccine has hVIVO upbeat
31st Oct 2018 12:33
(Sharecast News) - Clinical development services business hVIVO confirmed on Wednesday that the National Institutes of Health had presented partial preliminary results from the recently-completed Phase I study of AGS-v at the American Society of Tropical Medicine and Hygiene's 67th annual conference in New Orleans.
Read morehVIVO lauds sales pipeline and large contract as revenues jump
20th Sep 2018 11:58
(Sharecast News) - Drug development services provider hVIVO achieved its "strongest potential sales pipeline" for several years, executive chairman Trevor Phillips said on Thursday.
Read morehVIVO revises expectations after accounting anomaly
21st Sep 2016 14:24
(ShareCast News) - Specialty biopharma company with clinical testing capabilities, hVIVO, announced a trading update regarding the accounting treatment of the company's joint venture investment in Imutex on Wednesday. The AIM-traded firm said that due to accounting rules, revenue from the Phase IIa
Read morehVIVO launches groundbreaking asthma study
2nd Sep 2016 10:18
(ShareCast News) - Human disease models pioneer hVIVO announced on Friday that its landmark asthma stratification initiative is now underway, with the first volunteer inoculated with human rhinovirus at hVIVO's London-based clinical research unit. The AIM-traded firm said the hVIVO asthma stratifica
Read more